Health technology assessment in cancer: A personal view from public health

被引:0
作者
Waugh, Norman [1 ]
机构
[1] Univ Aberdeen, Dept Publ Hlth, Aberdeen AB25 2ZD, Scotland
关键词
cancer; health technology assessment; cost-effectiveness; utility; health economics;
D O I
10.1016/j.ejca.2006.08.009
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Health technology assessment (HTA) poses three main questions: does it work? at what cost? is it worth it? Since funds for health care are always finite, it will not be possible to provide every form of care that may do some good for some people. Hard choices have to be made. HTA is a form of policy analysis that helps decide what to fund and what not to fund. Tensions arise mainly when a new intervention is clinically effective but not cost-effective, usually because the benefit is small and the cost high. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2876 / 2880
页数:5
相关论文
共 8 条
  • [1] [Anonymous], HLTH TECHNOL ASSESS
  • [2] [Anonymous], HLTH TECHNOL ASSESS
  • [3] [Anonymous], HLTH TECHNOL ASSESS
  • [4] Banta HD, 1993, HLTH CARE TECHNOLOGY
  • [5] Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer
    Joensuu, H
    Kellokumpu-Lehtinen, P
    Bono, P
    Alanko, T
    Kataja, V
    Asola, R
    Utriainen, T
    Kokko, R
    Hemminki, A
    Tarkkanen, M
    Turpeenniemi-Hujanen, T
    Jyrkkiö, S
    Flander, M
    Helle, L
    Ingalsuo, S
    Johansson, K
    Jääskeläinen, A
    Pajunen, M
    Rauhala, M
    Kaleva-Kerola, J
    Salminen, T
    Leinonen, M
    Elomaa, I
    Isola, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (08) : 809 - 820
  • [6] Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
    Piccart-Gebhart, MJ
    Procter, M
    Leyland-Jones, B
    Goldhirsch, A
    Untch, M
    Smith, I
    Gianni, L
    Baselga, J
    Bell, R
    Jackisch, C
    Cameron, D
    Dowsett, M
    Barrios, CH
    Steger, G
    Huang, CS
    Andersson, M
    Inbar, M
    Lichinitser, M
    Láng, I
    Nitz, U
    Iwata, H
    Thomssen, C
    Lohrisch, C
    Suter, TM
    Ruschoff, J
    Süto, T
    Greatorex, V
    Ward, C
    Straehle, C
    McFadden, E
    Dolci, MS
    Gelber, RD
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16) : 1659 - 1672
  • [7] National Institute for Clinical Excellence and its value judgments
    Rawlins, MD
    Culyer, AJ
    [J]. BRITISH MEDICAL JOURNAL, 2004, 329 (7459): : 224 - 227
  • [8] How should different life expectancies be valued?
    Waugh, N
    Scott, D
    [J]. BRITISH MEDICAL JOURNAL, 1998, 316 (7140) : 1316 - 1316